US Edition
Published • loading... • Updated
MAIA Pharmaceuticals Selected by Asahi Kasei Pharma to Advance Teribone™ for US Osteoporosis Patients
Summary by THE TIMES OF BENGAL
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
MAIA Pharmaceuticals Selected by Asahi Kasei Pharma to Advance Teribone™ for US Osteoporosis Patients
A proven bone-forming osteoporosis therapy optimized for real-world use and patient compliance PRINCETON, N.J., Feb. 19, 2026 /PRNewswire/ — MAIA Pharmaceuticals, Inc. today announced a strategic collaboration with Asahi Kasei Pharma Corp., under which MAIA will advance Teribone (teriparatide) for the treatment of osteoporosis in the United States. Teribone is an established bone-forming therapy with more than a decade of clinical use in Japan a…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
